Haleon Plc first quarter sales rise 2.2% but miss analyst estimates

12 articles · Updated · Bloomberg · Apr 29

The maker of Panadol and Advil reported sales growth below the 2.4% expected by analysts for the first quarter of 2026.
Weaker demand for over-the-counter cold and flu medicines at the start of the year contributed to the shortfall.
The company’s performance highlights ongoing challenges in consumer health demand, particularly for seasonal remedies, impacting overall sales momentum.

Could Haleon's weak Q1 sales signal a long-term shift in how consumers approach cold and flu remedies?

With declining cold and flu activity, what new growth areas could offset losses for OTC medicine manufacturers?

How might unexpected changes in disease patterns disrupt revenue forecasts for healthcare companies in 2026 and beyond?

How might Haleon's cost-saving strategy and R&D investments reshape its product lineup in a changing OTC market?

Are regulatory warnings on key ingredients like acetaminophen and NSAIDs permanently altering consumer trust in OTC medicines?